Authors:
Rex, JH
Walsh, TJ
Nettleman, M
Anaissie, EJ
Bennett, JE
Bow, EJ
Carillo-Munoz, AJ
Chavanet, P
Cloud, GA
Denning, DW
de Pauw, BE
Edwards, JE
Hiemenz, JW
Kauffman, CA
Lopez-Berestein, G
Martino, P
Sobel, JD
Stevens, DA
Sylvester, R
Tollemar, J
Viscoli, C
Viviani, MA
Wu, T
Citation: Jh. Rex et al., Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses, CLIN INF D, 33(1), 2001, pp. 95-106
Authors:
Klijn, JGM
Blamey, RW
Boccardo, F
Tominaga, T
Duchateau, L
Sylvester, R
Citation: Jgm. Klijn et al., Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials, J CL ONCOL, 19(2), 2001, pp. 343-353
Authors:
Jakse, G
Hall, R
Bono, A
Holtl, W
Carpentier, P
Spaander, JP
van der Meijden, APM
Sylvester, R
Citation: G. Jakse et al., Intravesical BCG in patients with carcinoma in situ of the urinary bladder: Long-term results of EORTC GU group phase II protocol 30861, EUR UROL, 40(2), 2001, pp. 144-150
Authors:
Duchateau, L
Pignon, JP
Bijnens, L
Bertin, S
Bourhis, J
Sylvester, R
Citation: L. Duchateau et al., Individual patient-versus literature-based meta-analysis of survival data:Time to event and event rate at a particular time can make a difference, an example based on head and neck cancer, CONTR CL TR, 22(5), 2001, pp. 538-547
Authors:
van der Meijden, APM
Brausi, M
Zambon, V
Kirkels, W
de Balincourt, C
Sylvester, R
Citation: Apm. Van Der Meijden et al., Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: A European organization for research andtreatment of cancer genito-urinary group randomized phase III trial, J UROL, 166(2), 2001, pp. 476-481
Authors:
Mack, D
Holtl, W
Bassi, P
Brausi, M
Ferrari, P
de Balincourt, C
Sylvester, R
Citation: D. Mack et al., The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder, J UROL, 165(2), 2001, pp. 401-403
Citation: R. Sylvester et C. Sternberg, The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: What we do not know and why, ANN ONCOL, 11(7), 2000, pp. 851-856
Authors:
Paridaens, R
Biganzoli, L
Bruning, P
Klijn, JGM
Gamucci, T
Houston, S
Coleman, R
Schachter, J
Van Vreckem, A
Sylvester, R
Awada, A
Wildiers, J
Piccart, M
Citation: R. Paridaens et al., Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European organization for research and treatment of cancer randomized study with cross-over, J CL ONCOL, 18(4), 2000, pp. 724-733
Authors:
Dalesio, O
van Tinteren, H
Clarke, M
Peto, R
Schroder, FH
Dechering, I
Evans, V
Godwin, J
Blumenstein, BA
Crawford, ED
Denis, L
Hall, R
Hill, C
Iversen, P
Shipley, WU
Soloway, M
Sylvester, R
Citation: O. Dalesio et al., Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials, LANCET, 355(9214), 2000, pp. 1491-1498
Authors:
Julien, JP
Bijker, N
Fentiman, IS
Peterse, JL
Delledonne, V
Rouanet, P
Avril, A
Sylvester, R
Mignolet, F
Bartelink, H
Van Dongen, JA
Citation: Jp. Julien et al., Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853, LANCET, 355(9203), 2000, pp. 528-533
Authors:
Van Der Meijden, A
Sylvester, R
Collette, L
Bono, A
Ten Kate, F
Citation: A. Van Der Meijden et al., The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: A combined analysis of 5 European organization for research and treatment of cancer trials, J UROL, 164(5), 2000, pp. 1533-1537
Authors:
Duchateau, L
Collette, L
Sylvester, R
Pignon, JP
Citation: L. Duchateau et al., Estimating number of events from the Kaplan-Meier curve for incorporation in a literature-based meta-analysis: What you don't see you can't get!, BIOMETRICS, 56(3), 2000, pp. 886-892
Authors:
van Tienhoven, G
Voogd, AC
Peterse, JL
Nielsen, M
Andersen, KW
Mignolet, F
Sylvester, R
Fentiman, IS
van der Schueren, E
van Zijl, K
Blichert-Toft, M
Bartelink, H
van Dongen, JA
Citation: G. Van Tienhoven et al., Prognosis after treatment for loco-regional recurrence after mastectomy orbreast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM), EUR J CANC, 35(1), 1999, pp. 32-38
Authors:
Blom, JHM
van Poppel, H
Marechal, JM
Jacqmin, D
Sylvester, R
Schroder, FH
de Prijck, L
Citation: Jhm. Blom et al., Radical nephrectomy with and without lymph node dissection: Preliminary results of the EORTC randomized phase III protocol 30881, EUR UROL, 36(6), 1999, pp. 570-575
Citation: R. Sylvester et L. Collette, Statistical considerations of chemoprevention clinical trials in prostate cancer, EUR UROL, 35(5-6), 1999, pp. 519-522
Authors:
van der Meijden, A
Oosterlinck, W
Brausi, M
Kurth, KH
Sylvester, R
de Balincourt, C
Citation: A. Van Der Meijden et al., Significance of bladder biopsies in Ta,T1 bladder tumors: A report from the EORTC Genito-Urinary Tract Cancer Cooperative Group, EUR UROL, 35(4), 1999, pp. 267-271
Authors:
Ellis, M
Spence, D
de Pauw, B
Meunier, F
Marinus, A
Collette, L
Sylvester, R
Meis, J
Boogaerts, M
Selleslag, D
Kremery, V
von Sinner, W
MacDonald, P
Doyen, C
Vandercam, B
Citation: M. Ellis et al., An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis, CLIN INF D, 27(6), 1998, pp. 1406-1412